2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Best Practices in Immunotherapy – June/July 2017 Vol 8 | July 19, 2017
A new study has shown that combination immunotherapy can yield significant clinical benefits—even in heavily pretreated populations.
Best Practices in Immunotherapy – June/July 2017 Vol 8 | July 19, 2017
New research into gut bacteria may shed light on the mystery of responsiveness to immunotherapy. The multi-institutional study, presented at the 2017 ASCO-SITC Clinical Immuno-Oncology Symposium, showed that patients with metastatic melanoma who responded to anti—PD-1 agents had increased diversity of intestinal microbiome.
Best Practices in Immunotherapy – June/July 2017 Vol 8 | July 19, 2017
When combined with chemotherapy, a vaccine against the human papillomavirus type 16 (HPV16) elicited strong T-cell responsiveness and improved clinical outcomes in patients with advanced cervical cancer.
Best Practices in Immunotherapy – June/July 2017 Vol 8 | July 19, 2017
According to data presented at the 2017 ASCO-SITC Clinical Immuno-Oncology Symposium, adoptive T-cell transfer using “nonengineered” T cells is producing durable responses in heavily pretreated patients with lymphoma or multiple myeloma.
Best Practices in Immunotherapy – June/July 2017 Vol 8 | July 19, 2017
In patients with stage III/IV melanoma, intratumoral injections of plasmid interleukin-12 (IL-12) via electroporation enhanced response to immune checkpoint blockade.
Best Practices in Immunotherapy – June/July 2017 Vol 8 | July 19, 2017
The advent of immunotherapy has led to durable clinical responses in a variety of malignancies, but identifying which patients will respond to treatment remains an elusive goal.
Best Practices in Immunotherapy – June/July 2017 Vol 8 | July 19, 2017
As Dr Mita reported at the 2017 ASCO-SITC Clinical Immuno-Oncology Symposium, plinabulin is a small molecule with tumor-inhibiting and immune-enhancing effects.
Best Practices in Immunotherapy – June/July 2017 Vol 8 | July 19, 2017
Durability of benefit—the possibility for sustained remission in patients with previously incurable disease—is already one of the hallmarks of immunotherapy. According to recent statistical analysis, however, this durability may even exceed expectations.
Best Practices in Immunotherapy – June/July 2017 Vol 8 | July 19, 2017
According to data presented at the 2017 ASCO-SITC Clinical Immuno-Oncology Symposium, a single intravenous dose of an oncolytic virus can be highly effective in disseminated cancer as well.
Best Practices in Immunotherapy – June/July 2017 Vol 8 | July 19, 2017
According to preliminary data presented at the 2017 ASCO-SITC Clinical Immuno-Oncology Symposium, when used in combination with either ipilimumab or pembrolizumab, talimogene laherparepvec (T-VEC) demonstrated promising efficacy with minimal added toxicity.
- 1
- 2
Page 1 of 2
Results 1 - 10 of 11
Results 1 - 10 of 11